• “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 来宝网Logo

    热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

    现在位置时时彩网络平台>技术资料首页>行业动态>公司动态>Albany以2700万美元收收购 Hyaluron

    盐城快速路里程: Albany以2700万美元收收购 Hyaluron

    AMRI2010年6月21日 18:18 点击:2227

    时时彩网络平台 www.qlgr.net

    AMRI以2700万美元收收购 Hyaluron


     

     June 15, 2010

    AMRI Acquires Hyaluron Inc.

    AMRI Expands Integrated Contract Services Platform to include Sterile Fill and Finish Capabilities

    • Immediate entry into high growth prefilled syringe market
    • Expansion of customer base for AMRI’s existing Discovery/Development/Small Scale and Large Scale business
    • Acquisition of patented Bubble Free FillingTM Technology
    • Furthers AMRI strategy to acquire new technologies and expand integrated services platform
    • Acquisition accretive to AMRI E.P.S. within first year

    Albany, NY (June 15, 2010) -- AMRI (NASDAQ: AMRI) today announced the acquisition of Hyaluron Inc., expanding AMRI’s contract manufacturing capabilities to include cGMP manufacturing and sterile filling of parenteral drugs to the biopharmaceutical industry. AMRI has acquired all facilities and equipment as well as a highly trained and experienced staff of professionals with expertise in sterile GMP manufacturing. Purchase price, including debt, was approximately $27 million.

    Hyaluron provides high value-added contract manufacturing services in sterile syringe and vial filling using specialized technologies including lyophilization and Bubble-Free FillingTM, a unique patented technology developed and owned by Hyaluron. Hyaluron provides these services for both small molecule drug products as well as biologicals, from clinical phase to commercial scale.

    Hyaluron is one of a small number of organizations with prefilled syringe capabilities in the United States. In 2008, the company announced the grant of a patent for its proprietary process for aseptic online vacuum filling and online vacuum stoppering of low viscosity liquids in syringes called Bubble-Free FillingTM.

    This acquisition provides AMRI immediate entry into a new and strategically important product offering. AMRI can now offer customers a fully integrated manufacturing process for sterile injectable drugs including the development and manufacture of the active pharmaceutical ingredient (API), the design of the criteria to formulate the API into an injectable drug product, and the manufacture of the final drug product.

    “AMRI is excited to announce our entry into the rapidly growing sterile fill injectables market, including capabilities to formulate and manufacture protein-containing drug products,” said AMRI Chairman and CEO Thomas E. D’Ambra, Ph.D. “This acquisition immediately expands the synergies we can offer to our customers, by providing services in preparation of active ingredients and finished dosage form.”

    “We believe that the unique capabilities of both organizations will quickly assimilate into a larger, fully integrated GMP manufacturing provider of choice for companies desiring to capitalize on seamless technology transfer and the related increased efficiency and cost benefits of such a model,” continued Dr. D’Ambra. “It is a pleasure to congratulate the founders and staff of Hyaluron for building a promising and growing business. We look forward to welcoming them into the AMRI organization.”

    Hyaluron founder and President Shawn Kinney, Ph.D. said, “We look forward to becoming a vital part of AMRI’s full service global organization. Similar to AMRI, we expect that the synergies between our service offerings will provide a win for not only AMRI and Hyaluron, but more importantly for customers seeking the best in value, quality and customer service.”

    Dr. Kinney will continue in his role as site leader of the Hyaluron business unit, which will operate as a subsidiary of AMRI.
    Hyaluron forecasts full year 2010 revenue to be $15 to $17 million, up from $13 million for the full year 2009.
    BroadOak Partners acted as financial advisor to AMRI.


    About AMRI
    Founded in 1991, Albany Molecular Research, Inc. provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world’s leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the United States, Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

    About Hyaluron
    Hyaluron aseptically fills liquid and lyophilized products into syringes, vials, and custom containers. In addition to traditional formulations, Hyaluron excels in process development scale up of difficult formulations including: emulsions; viscous gels; suspensions, liposomes, and proteins.

    Forward-looking Statements
    Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words and include, without limitation, statements by Dr. D’Ambra and Dr. Kinney, statements concerning the proposed acquisition, the terms and the timing of the acquisition and statements concerning earnings per share and costs. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to, the reaction of customers of the company and Hyaluron to the acquisition; the company’s timing and ability to successfully integrate Hyaluron’s operations (including migration of Hyaluron to the company’s systems and controls) and employees; the introduction of new services by competitors or the entry of new competitors into the markets for the company’s and Hyaluron services; the failure by the company to retain key employees of Hyaluron; failure to further develop and successfully market Hyaluron service offerings; failure to achieve anticipated revenues and earnings; costs related to the acquisition; the company's ability to attract and retain experienced scientists; trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development; the company's ability to enforce its intellectual property and technology rights; the risks posed by international operations to the company; and the company's ability to effectively manage its growth, as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2009 as filed with the Securities and Exchange Commission on March 12, 2010 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.
     

    Contacts:

    Investors – Peter Jerome, AMRI Director of Investor Relations, 518-512-2220
    Media – Andrea Schulz, AMRI Director of Corporate Communications, 518-512-2226

    (来源: AMRI )


    全年征稿 / 资讯合作

    联系邮箱:[email protected]

    版权与免责声明

    • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, 时时彩网络平台,违反者本网将追究相关法律责任。
    • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
    • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


  • “蛟龙” 吸引世界目光(砥砺奋进的五年·重大工程巡礼) 2019-08-19
  • 李克强:扩大跨省异地就医直接结算范围 2019-08-11
  • 次仁卓玛一家的端午节 2019-08-11
  • 市人大常委会召开党组会议传达学习全国两会精神张轩主持并讲话 2019-08-09
  • 世界杯期间在家撸串的正确姿势-热门标签-华商网数码 2019-08-06
  • 兴业银行获第十二届人民企业社会责任奖年度企业奖 2019-08-02
  • 宝马中国创新日暨上海研发中心揭幕 专注于高新技术 2019-08-01
  • 解放军报评论员:担当起党和人民赋予的新时代使命任务 2019-08-01
  • 别人家的中年男子 听音识木一把琴能卖30万 2019-07-18
  • 《贪婪之秋》延期至2019年 E3新宣传片公开 2019-06-25
  • 《关于发展租赁型职工集体宿舍的意见(试行)》正式发布实施 2019-06-24
  • 网约车陷阱多 谨防四类风险 2019-06-19
  • 太原设禁鸣路段 设备在测试中 2019-06-19
  • 歌浴森专辑写真曝光 俏皮可爱萌态十足 2019-06-09
  • 破11个赛季不胜魔咒 山东客场击败广厦 2019-06-09
  • 福彩3d千禧开机号码 乒乓球鞋品牌 河南11选5历史开奖号码是多少钱 福建十一选五彩票app 双色球069历史开奖号 大乐透开奖走势图 香港赛马会资料免费一 广西快乐双彩基本走势图表 平特一肖公式计算器 宁夏11选5走势 25选5开奖结果 澳洲幸运10开奖网址 中原中原风采22选5走势图 彩票书籍 内蒙古时时彩彩开奖结果查询